CONCLUSION


Continue Reading

The management of MPM remains a significant challenge, and the prognosis for the vast majority of patients afflicted with this disease remains poor. While the decreased use of asbestos in industry will gradually reduce the worldwide burden of MPM, it is predicted that the incidence of the disease across the world will continue to rise for several decades before the effects of decreased asbestos use are realized. In addition, up to 20% of patients with MPM do not have clear prior asbestos exposure, arguing that the disease will not be eliminated completely in the “post-asbestos” era. Therefore, it is imperative that novel and improved therapies for MPM continue to be developed. At present, most fit patients with MPM are offered platinum-based chemotherapy combinations that modestly improve survival. Surgery and multimodality therapy are offered to selected patients at experienced centers but without clear evidence to truly define the magnitude of benefit of that approach. Recent successes with the addition of bevacizumab to standard chemotherapy and with the possibility of antitumor effects with the immune checkpoint inhibitors in MPM give hope that a better understanding of the biology of this disease will gradually lead to improved outcomes for these patients.

Disclosure

Jonathan Dowell has disclosed that he has received research support from MedImmune, LLC and Verastem, Inc. Shivani Patel has no relevant financial interests to disclose. The authors report no conflicts of interest in this work.


Shivani C. Patel,1 Jonathan E. Dowell1,2

1Division of Hematology and Oncology, University of Texas Southwestern, 2Section of Hematology and Oncology, Veterans Affairs North Texas Healthcare System, Dallas, TX, USA 


References

1. Carbone M, Ly VH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227:44–58.

2. Chirieac LR, Barletta JA, Yeap BY, et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013;31(36):4544–4549.

3. Gibb H, Fulcher K, Nagarajan S, et al. Analyses of radiation and mesothelioma in the US Transuranium and Uranium Registries. Am J Public Health. 2014;103(4):710–716.

4. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973–2012), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2015, based on the November 2014 submission. Available from: http://seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_17_mesothelioma.pdf. Accessed September 15, 2015.

5. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603.

6. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–496.

7. Nasu M, Emi M, Pastorino S, et al. High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015;10(2):565–576.

8. Cercek A, Zaderer M, Rimner A, et al. Confirmation of high prevalence of BAP1 inactivation in mesothelioma. J Clin Oncol. 2015;33(Suppl). Abstract 7564.

9. Testa J, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022–1025.

10. Cheung M, Talarchek J, Howard S, et al. Prevalence of BAP1 germline mutations in asbestos-exposed malignant mesothelioma cases and controls. Cancer Res. 2015;75(15 Suppl). Abstract 2752.

11. Thomas A, Chen Y, Yu T, Gill A, Prasad V. Distinctive clinical characteristics of malignant mesothelioma in young patients. Oncotarget. 2015;6(18):16766–16773.

12. Lee G, Light R, Musk W. Management of malignant pleural mesothelioma: a critical review. Curr Opin Pulm Med. 2000;6(40):267–274.

13. Astoul P. Pleural mesothelioma. Curr Opin Pulm Med. 1999;5(4):259–268.

14. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg. 1996;224:288–294.

15. van Meerbeeck JP, Scherpereel A, Surmont V, et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78:92–111.

16. Goldberg M, Imbernon E, Rolland P, et al. The French National Mesothelioma Surveillance Program. Occup Environ Med. 2006;63:390–395.

17. Husain AN, Colby T. Guidelines for pathologic diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2013;137:647–667.

18. Hjerpe A, Ascoli V, Bedrossian CWM, et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papinicolaou Society of Cytopathology. Diagn Cytopathol. 2015;43(7):563–576.

19. Hjerpe A, Ascoli V, Bedrossian CWM, et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papinicolaou Society of Cytopathology. Acta Cytol. 2015;59(1):2–16.

20. Hjerpe A, Ascoli V, Bedrossian CWM, et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: a secondary publication. Cytopathology. 2015;26(3):142–156.

21. Hjerpe A, Dobra K. Comments on the recently published “Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma”. Cancer Cytopathol. 2015;123(8):449–453.

22. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Cancer. 1993;72(2):389–393.

23. Loddenkemper R. Thoracoscopy – state of the art. Eur Respir J. 1998;11:213–221.

24. Metintas M, Ak G, Dundar E, et al. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions. Chest. 137;6:1362–1368.

25. Adams RF, Gray W, Davis RJO, et al. Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest. 2001;120(6):1798–1802.

26. Beauchamp HD, Kundra NK, Aranson R, et al. The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. Chest. 1992;102(4):1110–1112.

27. Boutin C, Schlesser M, Frenay C, et al. Malignant pleural mesothelioma. Eur Respir J. 1998;12:972–981.

28. Chakrabarti B, Sheard J, Warburton CJ, et al. The rold of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest. 2006;129(6):1549–1555.

29. Maskell NA, Gleeson FV, Davis RJO. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomized controlled trial. Lancet. 2003;361:1326–1331.

30. Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005;80:1988–1993.

31. Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant mesothelioma. World J Surg. 2001;25:201–217.

32. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–731.

33. Curran D, Shamoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145–152.

34. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000;55(9):731–735.

35. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol. 2005;23(1):184–189.

36. Steele JPC. Prognostic factors for mesothelioma. Hematol Oncol Clin N Am. 2005;19:1041–1052.

37. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol. 2009;27(12):2081–2090.

38. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MSO1): a multicentre randomized trial. Lancet. 2008;371:1685–1694.

39. Vogezang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644.